Pregled bibliografske jedinice broj: 1157457
Noninfectious Intermediate, Posterior, or Panuveitis: Results from the Retrospective, Observational, International EyeCOPE Study
Noninfectious Intermediate, Posterior, or Panuveitis: Results from the Retrospective, Observational, International EyeCOPE Study // Ophtalmology Therapy, 10(3) (2021), 565-580 doi:10.1007/s40123-021-00351-4. (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1157457 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Noninfectious Intermediate, Posterior, or
Panuveitis: Results from the Retrospective,
Observational, International EyeCOPE Study
Autori
Kramer Michal, Brichova Michaela, Tugal-Tutkun Ilknur, Panchenko Mykola, Gormezano Natali, Koenigsbauer Franziska, Franco Pablo, Muccioli Cristina, Hasanreisoglu Murat ; International EyeCOPE Study Group.
Kolaboracija
International EyeCOPE Study Group
Izvornik
Ophtalmology Therapy (2193-6528) 10(3)
(2021);
565-580
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Corticosteroid disease burden ; Disease characteristics ; Immunosuppressants ; Noninfectious uveitis ; Patient-reported outcomes.
Sažetak
Introduction: The EyeCOPE study characterized noninfectious intermediate posterior, or panuveitis (NIIPPU) before biologic agents were widely available. Methods: This retrospective, observational study included adults with NIIPPU attending a routine ophthalmological visit. Data were collected from the study visit and medical records. Results: Of 565 patients, 58.8% were female, and the mean age was 41.3 years ; 33.8% had idiopathic uveitis and 45.8% had panuveitis. The median time from symptom onset to diagnosis and treatment was 27.0 and 30.5 days, respectively. Patients received immunosuppressants and systemic/local corticosteroids. Most patients experienced substantial decline in ocular function (mean best corrected visual acuity, 0.4 logMAR). Mean total work productivity impairment among employed patients was 31.0%. Most patients reported ocular complications (70.8%) such as vision loss and cataracts. Conclusions: Despite treatment, most patients with NIIPPU experienced a decline in ocular function and ocular complications. There is an unmet need for additional NIIPPU treatment, such as targeted monoclonal antibodies.
Izvorni jezik
Engleski
Znanstvena područja
Kognitivna znanost (prirodne, tehničke, biomedicina i zdravstvo, društvene i humanističke znanosti)
POVEZANOST RADA
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Emerging Sources Citation Index (ESCI)
- Scopus